PharmAthene IncFind Ratings Reports
PHARMATHENE INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. PHARMATHENE INC is extremely liquid. Currently, the Quick Ratio is 5.94 which clearly shows the ability to cover any short-term cash needs. PIP managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 21.95% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY16||Q1 FY15|
|Net Sales ($mil)||1.01||7.07|
|Net Income ($mil)||-1.23||1.46|
|Balance Sheet||Q1 FY16||Q1 FY15|
|Cash & Equiv. ($mil)||14.24||15.73|
|Total Assets ($mil)||18.74||25.47|
|Total Debt ($mil)||0.0||0.5|
|Profitability||Q1 FY16||Q1 FY15|
|Gross Profit Margin||-120.87||46.1|
|Return on Assets||-32.72||-24.48|
|Return on Equity||-39.23||-31.13|
|Debt||Q1 FY16||Q1 FY15|
|Share Data||Q1 FY16||Q1 FY15|
|Shares outstanding (mil)||64.45||63.67|
|Div / share||0.0||0.0|
|Book value / share||0.24||0.31|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||308233.0||204303.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 10.35 indicates a significant premium versus the S&P 500 average of 2.80 and a discount versus the industry average of 10.73. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, PHARMATHENE INC proves to trade at a discount to investment alternatives within the industry.
|PIP NM||Peers 38.57||PIP NM||Peers 20.77|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
PIP's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PIP's P/CF is negative making the measure meaningless.
|PIP NA||Peers 111.79||PIP NA||Peers 1.06|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|PIP 10.35||Peers 10.73||PIP 9.10||Peers -16.43|
Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PIP is trading at a valuation on par with its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
PIP is expected to have an earnings growth rate that significantly exceeds its peers.
|PIP 35.32||Peers 370.84||PIP -66.13||Peers 40.78|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PIP is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
PIP significantly trails its peers on the basis of sales growth